$6.58 Million in Sales Expected for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) This Quarter

Equities analysts expect Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) to post $6.58 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Atara Biotherapeutics’ earnings, with the lowest sales estimate coming in at $5.70 million and the highest estimate coming in at $8.03 million. Atara Biotherapeutics reported sales of $3.55 million during the same quarter last year, which indicates a positive year-over-year growth rate of 85.4%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Atara Biotherapeutics will report full-year sales of $70.95 million for the current year, with estimates ranging from $24.00 million to $132.10 million. For the next financial year, analysts forecast that the company will report sales of $59.28 million, with estimates ranging from $11.00 million to $134.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last released its quarterly earnings data on Monday, February 28th. The biotechnology company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.36). The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $47.75 million. Atara Biotherapeutics had a negative net margin of 1,672.28% and a negative return on equity of 103.05%. During the same period in the previous year, the firm posted ($0.95) earnings per share.

Several research analysts have recently commented on ATRA shares. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Atara Biotherapeutics in a report on Thursday, January 27th. JPMorgan Chase & Co. reduced their target price on Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating on the stock in a report on Monday, March 28th. StockNews.com started coverage on Atara Biotherapeutics in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Finally, Canaccord Genuity Group reduced their target price on Atara Biotherapeutics from $78.00 to $67.00 in a report on Tuesday, March 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Atara Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $34.17.

In other Atara Biotherapeutics news, EVP Jakob Dupont sold 5,000 shares of the company’s stock in a transaction on Thursday, February 10th. The shares were sold at an average price of $16.00, for a total transaction of $80,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Utpal Koppikar sold 2,496 shares of the company’s stock in a transaction on Monday, February 7th. The shares were sold at an average price of $14.46, for a total transaction of $36,092.16. The disclosure for this sale can be found here. Insiders own 3.80% of the company’s stock.

Several institutional investors have recently modified their holdings of ATRA. Macquarie Group Ltd. raised its position in shares of Atara Biotherapeutics by 326.1% during the 3rd quarter. Macquarie Group Ltd. now owns 3,311 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,534 shares during the last quarter. Point72 Hong Kong Ltd raised its position in shares of Atara Biotherapeutics by 1,155.2% during the 3rd quarter. Point72 Hong Kong Ltd now owns 7,845 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 7,220 shares during the last quarter. LPL Financial LLC bought a new stake in shares of Atara Biotherapeutics during the 3rd quarter valued at $181,000. AlphaCrest Capital Management LLC acquired a new position in shares of Atara Biotherapeutics in the 4th quarter valued at $189,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of Atara Biotherapeutics in the 3rd quarter valued at $205,000.

Shares of ATRA opened at $6.36 on Friday. The company has a market capitalization of $562.33 million, a P/E ratio of -1.75 and a beta of 1.82. Atara Biotherapeutics has a one year low of $6.31 and a one year high of $20.04. The business’s 50 day simple moving average is $9.15 and its 200-day simple moving average is $13.75.

Atara Biotherapeutics Company Profile (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Stories

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.